Cargando…

The Potential of Lisosan G as a Possible Treatment for Glaucoma

Lisosan G (LG), a fermented powder obtained from whole grains, is a nutritional supplement containing a variety of metabolites with documented antioxidant properties. We have recently demonstrated that orally administered LG protects diabetic rodent retinas from oxidative stress, inflammation, apopt...

Descripción completa

Detalles Bibliográficos
Autores principales: Amato, Rosario, Rossino, Maria Grazia, Cammalleri, Maurizio, Timperio, Anna Maria, Fanelli, Giuseppina, Dal Monte, Massimo, Pucci, Laura, Casini, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355587/
https://www.ncbi.nlm.nih.gov/pubmed/34393798
http://dx.doi.org/10.3389/fphar.2021.719951
_version_ 1783736793235980288
author Amato, Rosario
Rossino, Maria Grazia
Cammalleri, Maurizio
Timperio, Anna Maria
Fanelli, Giuseppina
Dal Monte, Massimo
Pucci, Laura
Casini, Giovanni
author_facet Amato, Rosario
Rossino, Maria Grazia
Cammalleri, Maurizio
Timperio, Anna Maria
Fanelli, Giuseppina
Dal Monte, Massimo
Pucci, Laura
Casini, Giovanni
author_sort Amato, Rosario
collection PubMed
description Lisosan G (LG), a fermented powder obtained from whole grains, is a nutritional supplement containing a variety of metabolites with documented antioxidant properties. We have recently demonstrated that orally administered LG protects diabetic rodent retinas from oxidative stress, inflammation, apoptosis, blood-retinal barrier disruption, and functional damage. Here, we investigated whether LG may exert protective effects in a model of glaucoma and measured the amounts of selected LG components that reach the retina after oral LG administration. Six-month-old DBA/2J mice were given an aqueous LG solution in place of drinking water for 2 mo. During the 2 mo of treatment with LG, the intraocular pressure (IOP) was monitored and the retinal ganglion cell (RGC) functional activity was recorded with pattern-electroretinography (PERG). At the end of the 2-mo period, the expression of oxidative stress and inflammatory markers was measured with qPCR, and RGC survival or macroglial activation were assessed with immunofluorescence. Alternatively, LG was administered by gavage and the concentrations of four of the main LG components (nicotinamide, gallic acid, 4-hydroxybenzoic acid, and quercetin) were measured in the retinas in the following 24 h using mass spectrometry. LG treatment in DBA/2J mice did not influence IOP, but it affected RGC function since PERG amplitude was increased and PERG latency was decreased with respect to untreated DBA/2J mice. This improvement of RGC function was concomitant with a significant decrease of both oxidative stress and inflammation marker expression, of RGC loss, and of macroglial activation. All four LG metabolites were found in the retina, although with different proportions with respect to the amount in the dose of administered LG, and with different temporal profiles in the 24 h following administration. These findings are consistent with neuroenhancing and neuroprotective effects of LG in glaucoma that are likely to derive from its powerful antioxidant properties. The co-occurrence of different metabolites in LG may provide an added value to their beneficial effects and indicate LG as a basis for the potential treatment of a variety of retinal pathologies.
format Online
Article
Text
id pubmed-8355587
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83555872021-08-12 The Potential of Lisosan G as a Possible Treatment for Glaucoma Amato, Rosario Rossino, Maria Grazia Cammalleri, Maurizio Timperio, Anna Maria Fanelli, Giuseppina Dal Monte, Massimo Pucci, Laura Casini, Giovanni Front Pharmacol Pharmacology Lisosan G (LG), a fermented powder obtained from whole grains, is a nutritional supplement containing a variety of metabolites with documented antioxidant properties. We have recently demonstrated that orally administered LG protects diabetic rodent retinas from oxidative stress, inflammation, apoptosis, blood-retinal barrier disruption, and functional damage. Here, we investigated whether LG may exert protective effects in a model of glaucoma and measured the amounts of selected LG components that reach the retina after oral LG administration. Six-month-old DBA/2J mice were given an aqueous LG solution in place of drinking water for 2 mo. During the 2 mo of treatment with LG, the intraocular pressure (IOP) was monitored and the retinal ganglion cell (RGC) functional activity was recorded with pattern-electroretinography (PERG). At the end of the 2-mo period, the expression of oxidative stress and inflammatory markers was measured with qPCR, and RGC survival or macroglial activation were assessed with immunofluorescence. Alternatively, LG was administered by gavage and the concentrations of four of the main LG components (nicotinamide, gallic acid, 4-hydroxybenzoic acid, and quercetin) were measured in the retinas in the following 24 h using mass spectrometry. LG treatment in DBA/2J mice did not influence IOP, but it affected RGC function since PERG amplitude was increased and PERG latency was decreased with respect to untreated DBA/2J mice. This improvement of RGC function was concomitant with a significant decrease of both oxidative stress and inflammation marker expression, of RGC loss, and of macroglial activation. All four LG metabolites were found in the retina, although with different proportions with respect to the amount in the dose of administered LG, and with different temporal profiles in the 24 h following administration. These findings are consistent with neuroenhancing and neuroprotective effects of LG in glaucoma that are likely to derive from its powerful antioxidant properties. The co-occurrence of different metabolites in LG may provide an added value to their beneficial effects and indicate LG as a basis for the potential treatment of a variety of retinal pathologies. Frontiers Media S.A. 2021-07-28 /pmc/articles/PMC8355587/ /pubmed/34393798 http://dx.doi.org/10.3389/fphar.2021.719951 Text en Copyright © 2021 Amato, Rossino, Cammalleri, Timperio, Fanelli, Dal Monte, Pucci and Casini. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Amato, Rosario
Rossino, Maria Grazia
Cammalleri, Maurizio
Timperio, Anna Maria
Fanelli, Giuseppina
Dal Monte, Massimo
Pucci, Laura
Casini, Giovanni
The Potential of Lisosan G as a Possible Treatment for Glaucoma
title The Potential of Lisosan G as a Possible Treatment for Glaucoma
title_full The Potential of Lisosan G as a Possible Treatment for Glaucoma
title_fullStr The Potential of Lisosan G as a Possible Treatment for Glaucoma
title_full_unstemmed The Potential of Lisosan G as a Possible Treatment for Glaucoma
title_short The Potential of Lisosan G as a Possible Treatment for Glaucoma
title_sort potential of lisosan g as a possible treatment for glaucoma
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355587/
https://www.ncbi.nlm.nih.gov/pubmed/34393798
http://dx.doi.org/10.3389/fphar.2021.719951
work_keys_str_mv AT amatorosario thepotentialoflisosangasapossibletreatmentforglaucoma
AT rossinomariagrazia thepotentialoflisosangasapossibletreatmentforglaucoma
AT cammallerimaurizio thepotentialoflisosangasapossibletreatmentforglaucoma
AT timperioannamaria thepotentialoflisosangasapossibletreatmentforglaucoma
AT fanelligiuseppina thepotentialoflisosangasapossibletreatmentforglaucoma
AT dalmontemassimo thepotentialoflisosangasapossibletreatmentforglaucoma
AT puccilaura thepotentialoflisosangasapossibletreatmentforglaucoma
AT casinigiovanni thepotentialoflisosangasapossibletreatmentforglaucoma
AT amatorosario potentialoflisosangasapossibletreatmentforglaucoma
AT rossinomariagrazia potentialoflisosangasapossibletreatmentforglaucoma
AT cammallerimaurizio potentialoflisosangasapossibletreatmentforglaucoma
AT timperioannamaria potentialoflisosangasapossibletreatmentforglaucoma
AT fanelligiuseppina potentialoflisosangasapossibletreatmentforglaucoma
AT dalmontemassimo potentialoflisosangasapossibletreatmentforglaucoma
AT puccilaura potentialoflisosangasapossibletreatmentforglaucoma
AT casinigiovanni potentialoflisosangasapossibletreatmentforglaucoma